Previous 10 | Next 10 |
2023-08-09 17:15:39 ET Lantern Pharma press release ( NASDAQ: LTRN ): Q2 GAAP EPS of -$0.44 misses by $0.01 . Cash, cash equivalents, and marketable securities were approximately $48.0 million as of June 30. Shares +0.64% AH. For further details see: ...
Obtained FDA clearance of the IND application for LP-184 and activated initial clinical sites for the Phase 1 basket trial in relapsed/refractory advanced solid tumors and brain cancers - a patient population with unmet clinical needs. Completed IND-enabling studies for LP-284 and anticip...
New podcast series shines a spotlight on undervalued small-cap and microcap stocks ORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podc...
Webcast to be held Wednesday, August 9, 4:30 p.m. ET, register here , or at the link below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI an...
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR ® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announc...
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results supporting LP-284’s development for mant...
2023-06-12 13:44:30 ET Lantern Pharma ( NASDAQ: LTRN ) said the US Food and Drug Administration has cleared the company to begin Phase 1 testing of its drug candidate LP-184 for the treatment of cancerous solid tumors. Shares of Lantern were up 7% at $5.75 at 1:30 p.m. ET follow...
LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR ® . The first-in-human Phase 1A clinical trial has been cleared to proceed by the FDA and is anticipated to launch this summer for multiple advanced ...
Lantern will leverage its proprietary AI platform, RADR ® , to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates. The collaboration with Bielefeld University (Germany) will be led by Pro...
2023-05-19 06:50:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips AI penny stocks offer investors a thrilling opportunity to tap into the fast-evolving artificial intelligence space. AI penny stocks have limited financial resources and modest profits, but...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...